Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.

about

Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.

Item

http://www.wikidata.org/entity/Q52668197

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@en

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@nl

type

Item

label

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@en

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@nl

prefLabel

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@en

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@nl

P1476

Ruxolitinib significantly enha ...... mphoma xenograft murine model.

@en

P2093

Carmella van de Ven

http://www.w3.org/2001/XMLSchema#string

Changhong Yin

http://www.w3.org/2001/XMLSchema#string

Erin Morris

http://www.w3.org/2001/XMLSchema#string

Janet Ayello

http://www.w3.org/2001/XMLSchema#string

Jessica Hochberg

http://www.w3.org/2001/XMLSchema#string

Mitchell S Cairo

http://www.w3.org/2001/XMLSchema#string

Sanghoon Lee

http://www.w3.org/2001/XMLSchema#string

Tishi Shah

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.

P304

9776-9788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24267

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515770

http://www.w3.org/2001/XMLSchema#string

P921

xenograft

P932

5839401

http://www.w3.org/2001/XMLSchema#string